^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR T854A

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report. (PubMed, Medicine (Baltimore))
    Our study indicates that patients with NSCLC who are positive for uncommon EGFR T854A and T790M mutations might benefit from treatment with osimertinib.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR T854A
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib)
    almost2years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Chest Hospital | Trial primary completion date: Mar 2022 --> Oct 2022
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)
    2years
    Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer. (PubMed, Clin Lung Cancer)
    Presence of EGFR T854A mutation was rare in NSCLC patients and our retrospective study provides clinical evidence that osimertinib may be an effective treatment to improve survival outcomes in patients with EGFR T854A.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR C797S • EGFR exon 21 mutation • EGFR T854A
    |
    Tagrisso (osimertinib)
    over3years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Chest Hospital | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)
    over3years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Shanghai Chest Hospital
    Clinical • New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)